Target intelligence / Profile preview

Mesenchyme homeobox 1 (MEOX1)

Target
MEOX1
Molecular classification
Transcription factor, Homeobox protein
01

Overview

Mesenchyme homeobox 1 (MEOX1) is a DNA-binding transcription factor that belongs to the homeobox family. It is essential for development, particularly for somite segmentation—the process that separates the vertebrae—and for proper skeletal patterning. MEOX1 regulates the expression of other genes by binding to their promoters, and is critical for vertebral and cranio-cervical joint formation. Pathogenic mutations in MEOX1 cause Klippel-Feil syndrome, a disorder characterized by congenital fusion of cervical vertebrae. In adult tissues, MEOX1 drives fibroblast activation and fibrotic remodeling in response to TGF-β signaling, making it an attractive therapeutic target in cardiac fibrosis. Additionally, MEOX1 has complex, context-dependent roles in cancer biology and immune cell regulation[1][3][4][6][7].

Other names
Homeobox protein MOX-1MOX1MEOX1_HUMANKFS2
02

Mechanism of action

Not established for drugs; described as a potential druggable target in fibrotic disease, with experimental knockdown or inhibition impacting fibroblast activation and fibrosis[6].

03

Biological functions

Regulation of somite segmentation and vertebral developmentTranscription regulationMaintenance of skeletal patterningRegulation of fibroblast activation and tissue remodelingRole in osteogenic differentiation and skeletal homeostasisImmune regulation (notably in regulatory T cells)
04

Disease associations

Klippel-Feil syndrome (congenital fusion of cervical vertebrae)Cancer (oncogenic or tumor-suppressive, context-dependent; e.g., breast, ovarian, and lung cancers)Fibrosis (e.g. cardiac fibrosis via myofibroblast activation)Asthma (genetic association studies)
05

Safety considerations

Essential developmental gene; targeting carries risk of skeletal or developmental defects if off-target or systemic inhibition occurs[1][6].Context-dependent functions in cancer (can be oncogenic or tumor-suppressive)[4].
06

Biomarkers

No standard clinical biomarkers, though upregulation/overexpression can serve as a research biomarker in cancer prognosis (e.g., breast and lung cancer), cancer subgroups, and fibrotic tissue[4][6].

Beyond the preview

Go deeper on Mesenchyme homeobox 1 (MEOX1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mesenchyme homeobox 1 (MEOX1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call